# Fixed combination of palmitoylethanolamide and melatonin in preventive therapy of migraine: results from a randomized clinical trial

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/research/palmitoylethanolamide-for-migraine-randomized-controlled-trial/
> **Published:** 2026-10-24T12:00:20-04:00 | **Last Modified / Clinically Audited:** 2026-10-24T12:00:21-04:00
> **Clinical Summary:** This study looked at whether a nightly supplement combining a natural fatty compound called palmitoylethanolamide with the sleep hormone melatonin could.

---

Introduction: Migraines are neurological disorders which significantly impact quality of life. Current pharmacological treatments often have adverse effects, prompting the search for alternatives with fewer side effects. Several studies have described the antimigraine properties of palmitoylethanolamide (PEA) and melatonin. Materials and methods: The efficacy of the association of hydrodispersible PEA (1,200 mg) and melatonin (0.2 mg) was assessed by a randomized, three-month, double-blind, placebo-controlled trial (PEATONIDE; n = 30 patients; placebo; n = 30 patients). The primary outcome was the reduction of migraine frequency, while secondary outcomes included the reduction of intensity, duration, and grade of disability, assessed by a self-reported daily headache diary. Results: The formulation displayed a significant reduction in frequency (T3 months: 2.2 ± 0.4 MMDs; T0 baseline: 3.4 ± 0.5 MMDs, p < 0.001 vs baseline T0) and duration, intensity, disability, and incidence of associated symptoms after 3 months of treatment. No adverse effects were observed during the treatment. Conclusion: These findings suggest that PEATONIDE may be a promising adjunctive approach for migraine management. However, given the relatively small sample size, further large-scale and multicenter trials are needed to confirm its clinical applicability in broader migraine population.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).